Loss of placental growth factor protects mice against vascular permeability in pathological conditions

被引:77
作者
Luttun, A
Brusselmans, K
Fukao, H
Tjwa, M
Ueshima, S
Herbert, JM
Matsuo, O
Collen, D
Carmeliet, P [1 ]
Moons, L
机构
[1] Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium
[2] Kinki Univ, Sch Med, Dept Physiol, Osakasayama City, Japan
[3] Synthelabo LERS, Cardiovasc Thrombosis Res Dept, F-31036 Toulouse, France
关键词
PlGF; VEGF; vascular permeability; angiogenesis; skin wounds; neurogenic inflammation;
D O I
10.1016/S0006-291X(02)00677-0
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Vascular leakage contributes to numerous disorders but only a limited number of molecules have been demonstrated to modulate permeability of the vessel wall. The vascular endothelial growth factor (VEGF) is a potent inducer of vascular leakage. Previous studies demonstrated that exogenous administration of placental growth factor (PlGF), a homologue of VEGF, Stimulates vascular permeability but the role of endogenous PlGF in plasma extravasation during pathological conditions remains unknown. We recently generated PlGF deficient (PlGF(-/-)) mice and demonstrated that loss of PlGF impaired pathological angiogenesis by attenuating the response to VEGF. Here, we demonstrate that absence of PlGF reduces vascular leakage induced by skin wounding, allergens, and neurogenic inflammation. These findings suggest that inhibition of PlGF might be an attractive tool to reduce vascular leakage in various diseases. (C) 2002 Elsevier Science (USA). All rights reserved.
引用
收藏
页码:428 / 434
页数:7
相关论文
共 47 条
[1]   Placenta growth factor and vascular endothelial growth factor are co-expressed during early embryonic development [J].
Achen, MG ;
Gad, JM ;
Stacker, SA ;
Wilks, AF .
GROWTH FACTORS, 1997, 15 (01) :69-+
[2]  
ADACHI C, 1994, JPN J PHYSL, V24, P59
[3]   Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor [J].
Aiello, LP ;
Bursell, SE ;
Clermont, A ;
Duh, E ;
Ishii, H ;
Takagi, C ;
Mori, F ;
Ciulla, TA ;
Ways, K ;
Jirousek, M ;
Smith, LEH ;
King, GL .
DIABETES, 1997, 46 (09) :1473-1480
[4]  
AKOI Y, 2001, LEUKEMIA LYMPHOMA, V41, P229
[5]   Vascular leak syndrome: a side effect of immunotherapy [J].
Baluna, R ;
Vitetta, ES .
IMMUNOPHARMACOLOGY, 1997, 37 (2-3) :117-132
[6]   Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1 [J].
Barleon, B ;
Sozzani, S ;
Zhou, D ;
Weich, HA ;
Mantovani, A ;
Marme, D .
BLOOD, 1996, 87 (08) :3336-3343
[7]   Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor [J].
Baumgartner, I ;
Rauh, G ;
Pieczek, A ;
Wuensch, D ;
Magner, M ;
Kearney, M ;
Schainfeld, R ;
Isner, JM .
ANNALS OF INTERNAL MEDICINE, 2000, 132 (11) :880-884
[8]   EXPRESSION OF VASCULAR-PERMEABILITY FACTOR (VASCULAR ENDOTHELIAL GROWTH-FACTOR) BY EPIDERMAL-KERATINOCYTES DURING WOUND-HEALING [J].
BROWN, LF ;
YEO, KT ;
BERSE, B ;
YEO, TK ;
SENGER, DR ;
DVORAK, HF ;
VANDEWATER, L .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 176 (05) :1375-1379
[9]   Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions [J].
Carmeliet, P ;
Moons, L ;
Luttun, A ;
Vincenti, V ;
Compernolle, V ;
De Mol, M ;
Wu, Y ;
Bon, F ;
Devy, L ;
Beck, H ;
Scholz, D ;
Acker, T ;
DiPalma, T ;
Dewerchin, M ;
Noel, A ;
Stalmans, I ;
Barra, A ;
Blacher, S ;
Vandendriessche, T ;
Ponten, A ;
Eriksson, U ;
Plate, KH ;
Foidart, JM ;
Schaper, W ;
Charnock-Jones, DS ;
Hicklin, DJ ;
Herbert, JM ;
Collen, D ;
Persico, MG .
NATURE MEDICINE, 2001, 7 (05) :575-583
[10]  
CASALSSTENZEL J, 1987, IMMUNOPHARMACOLOGY, V13, P177